

# 学位論文の要旨

氏名 片倉 賢紀

学位論文名 Omega-3 Polyunsaturated Fatty Acids Enhance Neuronal Differentiation in Cultured Rat Neural Stem Cells

発表雑誌名 Stem Cells International  
(巻, 初頁~終頁, 年) (2013 巻, ID490476, 9 頁, 2013 年)

著者名 Masanori Katakura, Michio Hashimoto, Toshiyuki Okui, Shahdat Hossain, Kentaro Matsuzaki, Osamu Shido

## 論文内容の要旨

### INTRODUCTION

Polyunsaturated fatty acids (PUFAs), which are critical for the brain development, are classified into omega-3 PUFAs, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and omega-6 PUFAs, such as arachidonic acid (AA). Many of PUFAs, can not synthesize the required amount from their respective shorter-chain precursors in mammals. Thus, they need to be obtained from dietary sources. Dysregulation of fatty acid and phospholipid metabolism can induce a wide range of psychiatric, neurological, and developmental disorders in adults.

The enhancement of neurogenesis is an important tool to treat brain disorders and has been shown to ameliorate or prevent mental illnesses, cholinergic denervation, and neurodegenerative diseases. We hypothesized that PUFA treatment could prevent or recover these illness and diseases via activation of neurogenesis. Omega-3 PUFAs reportedly enhanced neurogenesis in adult rat brain and AA enhance proliferation and astrogenesis of fetal rat neuronal stem/progenitor cells (NSCs). However, the exact mechanisms of the beneficial effect of PUFAs on neurogenesis have not been elucidated.

Neurogenesis comprises the proliferation and differentiation of NSCs, which involves separate mechanisms; therefore, in the present study, we focused on differentiation of NSCs. Hes1, a repressor type of basic helix-loop-helix (bHLH) transcription factor, is essential for the maintenance and proliferation of NSCs, and their expression maintains the NSCs during embryogenesis. Activator-type bHLH transcription factors such as Hes6, neurogenin, Mash1, and NeuroD enhanced the expression of MAP2, a neuron specific protein, and induced neuronal

differentiation. Cross-talk between these two types of bHLH transcription factors allows some NSCs to undergo differentiation and maintain an NSC state. In the present study, we investigated that the effects of PUFAs on the expression levels of bHLH transcription factors and cell cycle in the NSCs.

## **MATERIALS AND METHODS**

NSCs were cultured by the neurosphere method. Rat forebrain cortices were isolated on E14.5. The cortices were mechanically disrupted into single cells by repeated pipetting in a serum-free conditioned medium (N2 medium). The dissociated cells were cultured in dishes in N2 medium with basic fibroblast growth factor (bFGF) and heparin in a humidified 5% CO<sub>2</sub>/95% air incubator at 37°C. Within 3-5 days, the cells grew as free-floating neurospheres that were then collected by centrifugation, mechanically dissociated by pipetting, and passaged. After the second passage neurospheres were mechanically dissociated and plated onto poly-L-ornithine-coated plates containing N2 medium without bFGF and heparin. The cultures were then treated with PUFAs (DHA, EPA, or AA; 1.0 µM) that were dissolved in N2 medium containing 1.0% fatty acid-free bovine serum albumin (BSA) at a final concentration of 0.01%. BSA was used as the vehicle control in this experiment and the culture medium was changed every other day. Cultured cells were fixed and stained with Tuj-1 (an immature neuron marker) or GFAP (a glia marker); then Tuj-1 and GFAP1 positive cells were counted. Total RNA was isolated and real-time polymerase chain reaction PCR was carried out with specific primers. Cell cycle analysis was performed using a 5-bromo-2'-deoxyuridine (BrdU) flow kit following to manufacturer's instruction. Cells were analyzed by fluorescence-activated cell sorting (FACS) using Becton Dickinson FACSCalibur flow cytometer.

## **RESULTS AND DISCUSSION**

Cell viability was analyzed using methyl thiazol tetrazolium (MTT) assay by treating with 1 µM of DHA, EPA, AA, or 0.01% BSA as a control for 4 days. No change in cell viability was detected in any-PUFA treated NSCs, indicating that 1 µM PUFA was not toxic to NSCs.

On day 4 after differentiation, neuronal cells were identified by staining with anti-Tuj-1 antibody in cells treated with 1 µM of DHA, EPA, or AA, whereas astrocytes were identified by staining with anti-GFAP antibody. Tuj-1-positive cells increased significantly after 4 and 7 d of DHA and EPA treatment, while no difference was observed in AA treated NSCs. These data indicated that omega-3 PUFAs, but not omega-6 PUFAs increased neuronal differentiation of NSCs.

Hes1 mRNA levels were decreased by DHA treatment on day 1 and 4, whereas EPA treatment increased Hes1 mRNA expression by 2.5-fold on day 1. AA treatment on day 4

significantly decreased Hes1 mRNA expression. Hes6, an inhibitor of Hes1, was also significantly increased by EPA treatment on day 1, but not on day 4. DHA and EPA treatment significantly increased NeuroD mRNA expression, but AA did not have any effect. The expression levels of Map2 mRNA significantly increased with DHA and EPA treatment, reflecting the change in Hes1, Hes6, and NeuroD expression levels in Tuj-1-positive cells. In the present study, we found that DHA and EPA enhanced neuronal differentiation in cultured NSCs. However, their target effector molecules are different. Our results indicated that EPA itself acts as an enhancer for neuronal differentiation and EPA did not serve solely as a precursor for DHA.

Next, we analyzed BrdU incorporation and total DNA content in differentiating NSCs treated with DHA, EPA, AA, or 0.01% BSA. Proliferating cells (S-phase cells) incorporated BrdU into their DNA and increased the FITC signal intensities. Cell cycle analysis 12 h after DHA and EPA treatment revealed a significant increase in the percentage of G0/G1-phase cells (control  $80.8 \pm 0.1\%$ ; DHA  $87.0 \pm 0.8\%$ ; and EPA  $88.5 \pm 0.2\%$ ) and a significant decrease in the percentage of S-phase cells (control  $15.4 \pm 0.1\%$ ; DHA  $8.4 \pm 0.5\%$ ; and EPA  $7.8 \pm 0.3\%$ ). On the other hand, following AA treatment,  $81.2 \pm 0.2\%$  of cells were in the G0/G1-phase,  $14.6 \pm 0.3\%$  in the S-phase, and  $2.4 \pm 0.2\%$  in the G2/M-phase. To confirm these results, mRNA expression levels of p21<sup>cip1</sup> and p27<sup>kip1</sup> (cyclin-dependent kinase inhibitors) were determined in PUFA-treated NSCs. p21<sup>cip1</sup> mRNA levels in the NSCs treated with DHA and EPA were 4.5- and 2.2-fold higher than in controls, respectively, and p27<sup>kip1</sup> mRNA levels were 2.5- and 2.3-fold higher than in controls, respectively. These data indicated that omega-3 PUFAs, but not AA induce cell cycle arrest by increasing p21<sup>cip1</sup> and p27<sup>kip1</sup> expression levels.

## CONCLUSION

DHA decreased Hes1 expression levels. EPA increased Hes6 expression levels, leading to decreased Hes1 activity. Decreased Hes1 activity increase NeuroD, Map2, p21<sup>cip1</sup>, and p27<sup>kip1</sup> expression levels. These mechanisms promote neuronal differentiation in NSCs.